Parveen Verma, DO
Endocrinology, Diabetes & Metabolism · Cherry Hill, NJNPI 1639149495
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,544 of the $73,361 with a category attached, or 89.3%. Boehringer Ingelheim accounts for 63.8% of it on its own, with 32 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $200.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$47K
- Lilly USA, LLC$21K
- Abbott$2K
- Antares Pharma, Inc.$619
- Novo Nordisk$601
- Medtronic$337
- plus $2K from 27 others
What the payments were for
- Consulting fees$4881%
- Speaking & faculty fees$65,54489%
- Travel & lodging$1280%
- Food & beverage$7,14610%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 68 | $46,822 |
| Lilly USA, LLC | 43 | $20,817 |
| Abbott | 73 | $1,677 |
| Antares Pharma, Inc. | 40 | $619 |
| Novo Nordisk | 32 | $601 |
| Medtronic(2 entities) | 6 | $337 |
| Bayer | 7 | $332 |
| Sanofi-aventis U.S. LLC | 17 | $301 |
| Insulet Corporation | 8 | $258 |
| Corcept Therapeutics | 5 | $174 |
| Madrigal Pharmaceuticals | 3 | $172 |
| Dexcom, Inc. | 5 | $165 |
| Tandem Diabetes Care, Inc. | 6 | $159 |
| Amgen | 9 | $135 |
| AstraZeneca | 9 | $125 |
| Exelixis Inc. | 1 | $118 |
| AbbVie | 6 | $87 |
| IBSA Pharma Inc. | 5 | $76 |
| Astellas Pharma US Inc | 3 | $55 |
| Halozyme Inc | 2 | $38 |
| Valeritas, Inc. | 2 | $35 |
| Tolmar, Inc. | 2 | $32 |
| Vivus LLC | 2 | $31 |
| Merck | 2 | $27 |
| Eisai Inc. | 2 | $26 |
| Radius Health, Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $22 |
| Companion Medical, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| BETA Bionics, Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$66,994
- Kerendia$228
- NOCDURNA$152
- XYOSTED$152
- Fortify Assura$149
- PTEYE PARATHYROID DETECTION SYSTEM$144
- FREESTYLE LIBRE 3$141
- REZDIFFRA$132
- RYBELSUS$125
- Cabometyx$118
- MINIMED 780G$117
- FreeStyle Libre$112
- Wegovy$106
- Korlym$100
How this compares
$73,361 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 217 | $426,841 |
| MounjaroTirzepatide | 142 | $255,226 |
| JardianceEmpagliflozin | 177 | $241,479 |
| TrulicityDulaglutide | 48 | $77,829 |
| FarxigaDapagliflozin Propanediol | 61 | $73,737 |
| JanuviaSitagliptin Phosphate | 50 | $64,444 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $61,541 |
| RybelsusSemaglutide | 29 | $57,564 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $55,516 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $48,342 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $40,961 |
| GlyxambiEmpagliflozin/Linagliptin | 22 | $38,734 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $36,685 |
| Bydureon BciseExenatide Microspheres | 29 | $34,911 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $34,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $601 | $484,405246 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $20,817 | $339,879203 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $46,822 | $308,109231 claims |
| AstraZenecaFarxiga | $125 | $73,73761 claims |
| MerckJanuvia | $27 | $64,44450 claims |
| Antares Pharma, Inc.Xyosted | $619 | $23,37223 claims |
| IBSA Pharma Inc.Tirosint | $76 | $8,72825 claims |
| AbbVieSynthroid | $87 | $8,10788 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Cherry Hill
- Gregory BaroneCherry Hill$433K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.